AUROX LIMITED

Financial Health Assessment: AUROX LIMITED

Here is the comprehensive financial health assessment for Aurox Limited, based on the filed financial history up to 31 December 2024.

1. Financial Health Score: C-

Explanation: Aurox Limited is currently in a state of "stable but guarded" condition. While the business has successfully recovered from previous periods of insolvency (negative net assets in 2019 and 2022) and is currently technically solvent, its financial immune system remains weak. The company is exhibiting acute symptoms of a cash flow squeeze, characterized by a massive buildup in inventory and debtors, which is placing significant pressure on its cash reserves and relying heavily on short-term creditor financing. The thin equity margin leaves little room for error.

2. Key Vital Signs

• Liquidity (Current Ratio): 1.88
  • Interpretation: Calculated as Current Assets (£671,608) divided by Current Liabilities (£357,687). On the surface, this looks like a healthy ratio, suggesting the company can cover its short-term debts. However, this metric is heavily skewed by the swelling inventory.
• Acid Test (Quick Ratio): 0.70
  • Interpretation: Calculated by excluding stock (£420,982) from current assets. A ratio below 1.0 indicates that without selling its inventory, the company cannot immediately cover its short-term liabilities. This is a symptom of "poor circulation"—cash is trapped in physical goods rather than being liquid.
• Net Assets (Equity): £23,019
  • Interpretation: While positive, this represents a very thin buffer (only 3% of total assets) against total liabilities of over £600k. The patient has recovered from negative equity in prior years, but the margin of safety is fragile.
• Cash Reserves: £89,931
  • Interpretation: Cash has dropped significantly from £155,875 in 2023 and £217,065 in 2022. This "lowering blood pressure" suggests cash is being consumed faster than it is being generated from operations.
• Inventory (Stock): £420,982
  • Interpretation: A staggering 124% increase from £187,815 in 2023. This is the primary "blockage" in the company's financial arteries.

3. Diagnosis

The Financial Data Reveals a Working Capital Absorption Crisis

Aurox Limited has a history of volatile financial health, swinging from positive net assets to negative net assets (insolvency) and back again. The 2024 accounts show a company that is technically solvent but suffering from severe "circulatory issues."

The core diagnosis is that the business is experiencing a Cash Flow Squeeze driven by Inventory Overhang and Creditor Reliance:

1. The Blockage (Inventory): The most alarming symptom is the more than doubling of stock levels to £421k. For a company manufacturing optical precision instruments, this represents either a deliberate build-up for anticipated large orders or, more concerningly, an inability to sell existing stock. This stock is currently "congesting" the balance sheet, tying up capital that cannot be used to pay creditors.
2. Rising Pressure (Creditors): To fund this inventory build-up and a near-doubling of debtors (from £87k to £160k), the company has significantly stretched its trade creditors (up from £82k to £117k) and increased its short-term bank loans. The business is essentially using supplier credit as a life-support system to fund its working capital cycle.
3. Provisions: There is a notable provision of £119k. While the nature isn't specified, provisions act as a drain on equity, further thinning the net asset base.
4. Positive Indicators: The news isn't all bad. Employee headcount has increased from 6 to 8, suggesting the business is investing in capacity. Furthermore, the P&L reserve has moved from a deficit to a small positive balance (£15,519), indicating that the company has returned to profitability at the bottom line, even if cash flow is strained.

4. Recommendations

To restore financial wellness and prevent a relapse into insolvency, the following immediate actions are recommended:

1. Clear the Arteries (Inventory Reduction): Management must urgently review the stock profile. A £421k inventory holding is disproportionate for a company of this size. Implement strategies to convert this stock into cash—consider discounting slow-moving items or halting production until the pipeline clears.
2. Improve Circulation (Debtor Collection): Debtors have nearly doubled. The company needs to tighten credit control procedures and accelerate invoice collection to convert these receivables into cash before creditor payment terms are due.
3. Manage the Pressure (Creditor Negotiation): Given the reliance on trade creditors, it is crucial to maintain strong relationships with suppliers. If cash flow remains tight, proactively negotiate extended payment terms rather than risking default.
4. Investigate Provisions: Review the £119k provision. If any of this relates to costs that can be deferred or does not represent a present obligation, releasing it would immediately strengthen the equity position.
5. Cash Flow Forecasting: The transition from high cash (£217k in 2022) to low cash (£89k in 2024) despite rising assets suggests a lack of liquidity planning. A 13-week rolling cash flow forecast is essential to ensure the business does not run out of cash.